Ireland-based biopharmaceutical company Jazz Pharmaceuticals plc (JAZZ) has agreed to acquire UK-based GW Pharmaceuticals plc (GWPH, GWP.L) for a total consideration of $7.2 billion, or $6.7 billion net of GW cash, the two companies said Wednesday.
Jazz Pharma noted that the acquisition of GW Pharma will expand its growing neuroscience business by adding Epidiolex, a global, high-growth childhood-onset epilepsy franchise with near-term blockbuster potential. Epidiolex is the first and only FDA-approved prescription cannabidiol medicine.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com